Hyperlipoproteinemias:
Indications for: LEQVIO
Adjunct to diet and statin therapy in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C.
Adult Dosage:
Give by SC inj into abdomen, thigh, or upper arm. Initially 284mg as a single inj, repeat at 3 months, and then every 6 months. Measure LDL-lowering effect as early as 30 days after initiation and anytime thereafter.
Children Dosage:
Not established.
LEQVIO Warnings/Precautions:
Do not inject into areas of active skin disease or injury (eg, sunburns, skin rashes, inflammation, skin infections). ESRD. Severe hepatic impairment. Pregnancy: avoid. Nursing mothers.
LEQVIO Classification:
Small interfering RNA (siRNA).
Adverse Reactions:
Inj site reaction, arthralgia, bronchitis.
Drug Elimination:
Renal (~16%). Half-life: ~9 hours.
Generic Drug Availability:
NO
How Supplied:
Single-dose prefilled syringe—1
